PRESS RELEASE

Heidelberg Pharma Announces Several Presentations of Research Results on ATAC Technology at the ASH Annual Meeting 2018

- Partner MD Anderson Cancer Center will present preclinical data on HDP-101 for effective 17p deletion in multiple myeloma in an oral presentation
- Partner Magenta will present data on the use of **A**ntibody **T**argeted **A**manitin **C**onjugates in the pre-treatment of patients with bone marrow transplants

Ladenburg, Germany, 2 November 2018 – Heidelberg Pharma AG (FSE: WL6) today announced that its collaboration partners MD Anderson Cancer Center, Houston, TX, USA, and Magenta Therapeutics, Cambridge, MA, USA, will present preclinical data at the 60th Annual Meeting of the American Society of Hematology (ASH), the leading convention for hematology. The meeting will take place from 1 to 4 December 2018 in San Diego, USA.

Prof. Andreas Pahl, CSO of Heidelberg Pharma AG, commented: "We are delighted that our research partner MD Anderson Cancer Center will present preclinical data on our product candidate HDP-101 in an oral presentation. The scientists at MD Anderson have now demonstrated that the Amanitin conjugate HDP-101 is able to fight tumor cells from patients with multiple myeloma with 17p deletion particularly well and efficiently. We are also proud that our licensing partner Magenta will present data with our ATAC technology at this important conference."

Oral Presentation of MD Anderson: HDP-101, a Novel B-Cell Maturation Antigen (BCMA)-Targeted Antibody Conjugated to α-Amanitin, Is Active Against Myeloma with Preferential Efficacy Against Pre-Clinical Models of Deletion 17p

Abstract #593
Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Development of Novel Immunotherapeutic Approaches in Multiple Myeloma
Presenter: Ram Kumar Singh, Ph.D., Department of Lymphoma/Myeloma, MD Anderson Cancer Center
Date: Monday, 3 December 2018
Session time: 7:00 am - 8:30 am PST
Presentation time: 8:00 am PST
Room: San Diego Convention Center, Ballroom 20D

Earlier studies with colorectal cancer cells published in Nature showed that Amanitin has the potential to act particularly well on tumors with aggressive progressions in connection with 17p deletion. “17p" refers to a section of the chromosome whose DNA contains the tumor suppressor gene TP53 as well as the gene for RNA polymerase II. Tumors often have a reduced TP53 function in order to weaken the natural tumor defence of the cells.

Since the 17p deletion also reduces the amount of RNA polymerase II, such tumor cells are particularly sensitive to Amanitin.

Poster presentations of Magenta

Magenta Therapeutics will present preclinical data obtained in different preclinical studies to improve treatment options in the field of bone marrow transplantation. The tested ADCs consist of antibodies from Magenta and the ATAC technology from Heidelberg Pharma and has been preclinically tested for its suitability for conditioning patients for the transplantation of bone marrow cells.

CD117-Amanitin Antibody Drug Conjugates Effectively Deplete Human and Non-Human Primate HSCs: Proof of Concept as a Targeted Strategy for Conditioning Patients for Bone Marrow Transplant

Abstract #3314
Session Name: 701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster II
Presenter: Brad Pearse, Ph.D., Magenta Therapeutics
Session Date: Sunday, 2 December 2018
Session Time: 6:00 pm - 8:00 pm PST
Room: San Diego Convention Center, Hall GH

Single Doses of Antibody Drug Conjugates (ADCs) Targeted to CD117 or CD45 Have Potent In Vivo Anti-Leukemia Activity and Survival Benefit in Patient Derived AML Models

Abstract #3316

Session Name: 701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster II
Presenter: Jennifer Proctor, Magenta Therapeutics
Session Date: Sunday, 2 December 2018
Session Time: 6:00 pm - 8:00 pm PST
Room: San Diego Convention Center, Hall GH

Targeting CD45 with an Amanitin Antibody-Drug Conjugate Effectively Depletes Human HSCs and Immune Cells for Transplant Conditioning

Abstract #4526
Session Name: 701. Experimental Transplantation: Basic Biology, Pre-Clinical Models: Poster III
Presenter: Rahul Palchaudhuri, Ph.D., Magenta Therapeutics

Session Date: Monday, 3 December 2018
Session Time: 6:00 pm - 8:00 pm PST
Room: San Diego Convention Center, Hall GH

All abstracts and additional information are available at the ASH conference website and will be published online in the supplemental November issue 2018 of the journal "Blood".

About Heidelberg Pharma's proprietary ATAC technology

Antibody drug conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.

About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates. The proprietary lead candidate is HDP-101, a BCMA ATAC for multiple myeloma.

The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON® and REDECTANE®, while RENCAREX® is available for out-licensing and further development. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.

Contact
Heidelberg Pharma AG
Corporate Communications
Sylvia Wimmer
Tel.: +49 89 41 31 38-29
Email: investors[at]hdpharma.com
Schriesheimer Str. 101, 68526 Ladenburg

IR/PR support
MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49 89 210 228-40
Email: katja.arnold[at]mc-services.eu

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.